The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence-Reference-Cited by-同舟云学术

The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence

Published:2015-01-24 Issue:5 Volume:33 Page:457-466
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Wade Ros,Duarte Ana,Simmonds Mark,Rodriguez-Lopez Rocio,Duffy Steven,Woolacott Nerys,Spackman Eldon

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40273-015-0257-z.pdf

Reference10 articles.

1. National Institute for Health and Clinical Excellence (NICE). Guide to the single technology appraisal (STA) process. London: NICE; 2006.

2. Wade R, Duarte A, Simmonds M, Rodriguez-Lopez R, Duffy S, Spackman E, et al. Aflibercept in combination with irinotecan and fluorouracil-based therapy for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy: a single technology appraisal. York: CRD and CHE Technology Assessment Group; 2013.

3. National Institute for Health and Care Excellence (NICE). Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307). London: NICE; 2014.

4. Cancer Research UK. Bowel cancer incidence statistics. 2014. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/incidence/uk-bowel-cancer-incidence-statistics . Accessed 29 Oct 2014.

5. Cancer Research UK. Bowel cancer survival statistics. 2014. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/survival/bowel-cancer-survival-statistics#one . Accessed 29 Oct 2014.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment;Frontiers in Pharmacology;2022-08-30

2. Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China;BMC Cancer;2020-10-13

3. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan;Clinical Therapeutics;2020-07

4. Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies;Frontiers in Oncology;2019-07-16

5. Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial;BMC Cancer;2017-11-17